efgartigimod alfa-ph20
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for efgartigimod alfa-ph20, covering 2025-12-05 to 2025-12-05. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis [Phase 2, Phase 3]